Skip to content
Buy This GLP
← Research
Evidence

REDEFINE 1: Semaglutide With Cagrilintide Cut Weight 20.4% at 68 Weeks

At 68 weeks, the CagriSema group lost an estimated 20.4% of body weight on average, versus 14.9% with semaglutide alone and 3.0% with placebo.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Estimated mean weight loss at week 68CagriSema20.4%Semaglutide14.9%Cagrilintide11.5%Placebo3.0%REDEFINE 1 · 3,417 adults randomized

What REDEFINE 1 tested

This 68-week randomized trial enrolled 3,417 adults without diabetes who had obesity or overweight with a weight-related complication. It assigned 2,108 to CagriSema, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo. The weekly target was 2.4 mg for each active component, and the protocol allowed dose adjustments. The CagriSema trials in type 2 diabetes answer a separate question in people with diabetes. In REDEFINE 1, every group received a lifestyle intervention [1].

How much did cagrilintide add?

The primary analysis estimated outcomes regardless of whether participants stayed on assigned treatment. At week 68, the combination produced an estimated 5.5 percentage points more weight loss than semaglutide alone (95% CI 4.3–6.7), 8.9 more than cagrilintide alone (7.7–10.1) and 17.3 more than placebo (16.6–18.1) [1]. The GLP-1 weight-loss evidence guide explains how the study population and follow-up period affect the interpretation of these averages.

Gastrointestinal adverse events occurred in 79.6% of the combination group, 73.8% of the semaglutide group, 54.0% of the cagrilintide group and 39.9% of the placebo group. The events were mainly temporary and mild to moderate, and included nausea, vomiting, diarrhea, constipation and abdominal pain[1].

U.S. regulatory status

Novo Nordisk submitted CagriSema for FDA review for weight management in December 2025. As of November 14, 2026, the combination remains investigational[2]. The FDA says cagrilintide cannot be used in compounding[3]. Research on compounded semaglutide injections concerns separate formulations and cannot establish the effects of the fixed-dose combination studied in REDEFINE 1.

Frequently asked

Did the combination produce more weight loss than semaglutide alone?
Yes. At 68 weeks, the estimated mean weight loss was 20.4% with CagriSema and 14.9% with semaglutide alone. The estimated difference was 5.5 percentage points (95% CI 4.3–6.7).
Is CagriSema available in the United States?
CagriSema remained investigational as of November 14, 2026. Novo Nordisk submitted it to the FDA for weight-management review in December 2025.
How common were digestive side effects?
Digestive side effects were reported by 79.6% of the combination group, 73.8% on semaglutide alone, 54.0% on cagrilintide alone and 39.9% on placebo. Most were temporary and mild to moderate.

Sources

  1. [1] Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. PMID 40544433
  2. [2] Novo Nordisk (2026). CagriSema clinical development and U.S. regulatory status Novo Nordisk. Source
  3. [3] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence